6 results about "Synthetic nucleotide" patented technology

The present disclosure discloses a method for synthesizing nucleotide strands, relating to the biology field. The synthesizing method includes regulating a temperature for synthesizing the nucleotide strands to ≥42° C. or performing a procedure of high-temperature denaturation-low-temperature annealing for at least one time during the synthesis, thus achieving efficient ligation of natural nucleic acid fragments and / non-natural nucleic acid fragments. This method can effectively reduce byproducts produced during the synthesis of nucleotide strands, improve the efficiency of synthesis of nucleotide strands of interest, and facilitate large-scale production of high-quality nucleotide strands.

This invention belongs to the field of biotechnology. It provides a recombinant protein whose amino acid sequence consists of two dominant epitopes of cardiac troponin I (cTnI) repeated in tandem. The amino acid sequence is converted into a corresponding nucleotide sequence using E. coli-preferred codons. The nucleotide sequence is then chemically synthesized and a recombinant expression vector is constructed, thereby increasing the expression level of the recombinant protein in E. coli. This invention also involves using this recombinant protein to immunize mice to establish a phage library, obtaining the corresponding cardiac troponin I single-chain antibody scfv sequence through panning and screening, constructing a complete mouse IgG1 antibody sequence expression vector from the obtained scfv sequence, expressing the monoclonal antibody via transient transfection of HEK293F cells, purifying the monoclonal antibody, and determining the optimal monoclonal antibody pairing using an immunofluorescence orthogonal experiment.

The present disclosure provides optionally modified small interfering ribonucleic acid (siRNA) compounds, pharmaceutical compositions, and methods of use thereof. The optionally modified siRNA compounds may be tailored to improve delivery to the central nervous system, to reduce off-target effects, and / or to reduce expression of mRNA transcribed from a gene of interest (e.g., LRRK2, VEGFA, or ANGPT2), i.e., to translate to a protein. In some embodiments, the sense strand of the siRNA comprises a synthetic nucleotide and / or a lipid conjugated to one or both ends of the sense strand, or within any position of the sense strand.

This disclosure provides a nucleotide dimer, its preparation method, and its uses, belonging to the field of nucleic acid drug technology. The nucleotide dimer can be synthesized as a whole into a nucleotide chain. Compared to synthesizing nucleotides one by one through two steps, the synthesis method using the nucleotide dimer provided in this disclosure involves fewer steps, higher synthesis efficiency, less impurities, and higher product purity, showing promising application prospects.

A composition for the synthesis of a nucleotide chain and a method for the synthesis of a nucleotide chain, belonging to the art of nucleotides. The composition for the synthesis of a nucleotide chain comprises a nucleotide fragment and a double-stranded ligase, wherein the nucleotide fragment is for forming a double-stranded structure, the double-stranded ligase is a ligase capable of closing gaps in the double-stranded structure, and at least one of the strands of the double-stranded structure is a target nucleotide chain, the nucleotide fragment comprises a first fragment and a second fragment, the first fragment contains a monophosphate group at its 5' end and the first fragment is synthesized in the direction from 3' to 5', the second fragment contains a hydroxyl group at its 3' end and the second fragment is synthesized in the direction from 5' to 3'.

The present invention provides for compositions and methods for deploying ddhNTPs as immunomodulatory therapeutics to modulate P2 receptors, as nucleotidase inhibitors, for applications like host-acting anti-infectives, oncolytics, anti-aging agents, or tissue regeneration agents.